8-K: Zivo Bioscience Sells 174,145 Shares in Private Placement

Zivo Bioscience sold 174,145 shares of its common stock to accredited investors in a private placement between January 4, 2024 and January 16, 2024.

Summary

• Zivo Bioscience, Inc. sold 174,145 shares of its common stock between January 4, 2024 and January 16, 2024.
• The shares were sold to accredited investors at prices ranging from $2.82 to $4.02 per share, with an average price of $3.05 per share.
• The sale was conducted as a private placement, without any solicitation or underwriting discounts.
• The company relied on exemptions from registration under Section 4(2) and Regulation D (Rule 506) of the Securities Act of 1933.
• As of January 16, 2024, Zivo Bioscience has 2,748,167 common stock shares outstanding.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company successfully raised capital, but the private placement may dilute existing shareholders. The lack of further details makes it difficult to assess the long-term impact.

Positives

• The company successfully raised capital through a private placement.
• The average price of $3.05 per share indicates investor interest.

Risks

• The private placement may dilute existing shareholders' ownership.
• The company's reliance on private placements for funding may indicate challenges in accessing public markets.

Industry Context

Private placements are a common method for smaller companies to raise capital, especially when access to public markets is limited. This is a typical approach for companies in the biotechnology sector.

Comparison to Industry Standards

• Private placements are a common method for raising capital in the biotech industry, particularly for companies that are not yet profitable or have limited access to public markets.
• The size of the placement and the average price per share are within the typical range for similar companies at this stage of development.
• Comparable companies often use private placements to fund research and development or to expand operations.

Stakeholder Impact

• Existing shareholders may experience dilution of their ownership due to the issuance of new shares.
• The capital raise provides the company with additional funding for operations and development.

Key Dates

Keywords

private placement, equity securities, common stock, accredited investors, capital raise, Zivo Bioscience